Diving headfirst into the generative artificial intelligence market, Ginkgo Bioworks said on Tuesday it plans to develop its own AI models for drug development and other synthetic biology applications ...
BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs ...
BOSTON, Dec. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with Deep Origin on a 4.5-year project funded by the Advanced Research Projects Agency for Health (ARPA ...
NEW YORK (Reuters Health) - Ginseng and ginkgo biloba fans may be relieved to learn that these two popular herbal supplements don't seem to alter how most prescription and over-the-counter drugs are ...
Tuesday, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced two tools to streamline the drug development process for pharmaceutical and biotech companies. Building on its partnership with Alphabet ...
BOSTON — Nov. 20, 2025 — Ginkgo Bioworks (NYSE: DNA) today announced the launch of the Virtual Cell Pharmacology Initiative (VCPI) through Ginkgo Datapoints. This open-source platform is designed to ...
Zymergen aimed to leave its well-publicized woes behind through a new-year transformation into a biotech. Now, the company has been picked up by Ginkgo Bioworks, which will look for “strategic ...
Plex has announced that it is partnering with Ginkgo Datapoints, a service of Gingko Bioworks, to use Plex’s artificial intelligence platform, Plex AI, to analyze the GDPx2 dataset, the latest release ...
The landscape of drug discovery has been dramatically shifting, thanks in large part to the influence of artificial intelligence (AI). Hosting unprecedented computational power and innovative ...
Ginkgo Bioworks has announced the launch of the Virtual Cell Pharmacology Initiative (VCPI) through Ginkgo Datapoints. This open-source platform is designed to build a standardized framework for ...
Ginkgo is teaming up with Synlogic to launch a new gout drug, moving shares of both stocks higher. -All right, shifting gears. Triple play is on deck, and here's what we're looking at. Ginkgo Bioworks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results